GlassScriptPhysician profile
Hiba Al-Dabagh
NPI 1487813630
$733.83
in general payments reported to CMS, 2019-2025
14 companies · $365 in 2025
The $365 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2021: $11.33 · 2023: $75.03 · 2024: $81.85 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $151.45 | 2024-2025 | Ozempic, Rybelsus |
| Corcept Therapeutics | $128.37 | 2019-2025 | Korlym |
| Abbott Laboratories | $74.54 | 2023-2024 | Freestyle Libre 3 |
| Amgen INC. | $72.15 | 2025 | Evenity, Tepezza |
| Mannkind Corporation | $59.40 | 2019 | |
| Sanofi-Aventis U.S. LLC | $51.52 | 2019-2021 | |
| Medtronic Minimed, INC. | $38.79 | 2019 | |
| Tandem Diabetes Care, INC. | $36.00 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $34.61 | 2023 | Dexcom G6 Transmitter |
| Amneal Pharmaceuticals LLC | $22.13 | 2025 | Unithroid |
| Lilly USA, LLC | $20.27 | 2025 | Mounjaro |
| Envista Holdings Corporation | $16.92 | 2025 | Maxcem Elite |
| Insulet Corporation | $15.45 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hiba Al-Dabagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.